Emeritus Professor of Diabetic Medicine
- Former Diabetes Trials Unit Director
- NIHR Senior Investigator
- Honorary Consultant Physician
The DTU is a fully registered UKCRC Clinical Trials Unit and a founder member of OCDEM. It is one of only a handful of Academic Research Organisations (AROs) worldwide that specialise in performing diabetes-related mega trials. The DTU designs, runs and analyses large-scale Phase III & IV interventional clinical outcome trials nationally and internationally, often in collaboration with other AROs and pharmaceutical companies. Currently the DTU is undertaking 4 large-scale cardiovascular outcome trials in 40 countries, multiple translational trials, holds grants in excess of £60M and has a regional coordinating centre in Beijing, China.
The DTU Translational Trials Group evaluates novel treatments and devices for the therapy of diabetes trials and undertakes research into potential new therapeutic agents in Phase IIa/b trials. The DTU also undertakes major modelling and statistical programmes to utilise fully the data available from its many studies with a particular emphasis on modelling diabetes and cardiovascular disease processes. The DTU Informatics Group designs and maintains the specialist departmental software, the automated data handling facilities and the in-house electronic clinical trials management systems.
Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).
Maddaloni E. et al, (2019), Diabetes Obes Metab, 21, 2115 - 2122
The importance of randomised vs non-randomised trials - Authors' reply.
Gerstein HC. et al, (2019), Lancet, 394
Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.
Guimarães PO. et al, (2019), Int J Cardiol, 289, 58 - 62
Comment on Kim et al. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks. Diabetes Care 2019;42:3-9.
Huo X. et al, (2019), Diabetes Care, 42
Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.
Dennis JM. et al, (2019), Diabetes Obes Metab, 21, 1576 - 1584